logo
Injectable asthma drug resolves dangerous food allergies in one-third of children

Injectable asthma drug resolves dangerous food allergies in one-third of children

Yahoo03-03-2025
More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an injectable asthma drug, new clinical trial findings report.
In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of the American Academy of Allergy, Asthma & Immunology in San Diego.
By comparison, only 19% of children could do the same when given a shorter round of omalizumab followed by months of oral immunotherapy, a treatment through which patients build tolerance by eating gradually increasing amounts of food allergens.
Further, early stage 3 results from the clinical trial found that children retained some resistance to food allergies even after they stopped taking omalizumab, researchers reported.
"This is the first time we've been able to directly compare these two treatments for multiple food allergies, and our study shows omalizumab was superior to oral immunotherapy," principal investigator Dr. Robert Wood, director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children's Center, said in a news release.
Food allergies are common, affecting 8% of U.S. children and 10% of adults, researchers said in background notes.
Omalizumab works by binding to the antibodies that promote allergic reactions, rendering them inactive, researchers said in background notes.
The drug has been on the market since 2003, first approved by the U.S. Food and Drug Administration as a preventive treatment for allergic asthma, according to Drugs.com.
And based on early results from this clinical trial, the FDA approved omalizumab as a treatment for food allergies in adults and children as young as 1 year old, researchers said in background notes.
The stage 2 clinical trial involved 117 children with an average age of 7 who were allergic to peanuts and at least two other common food allergens -- milk, egg, cashew, wheat, walnut or hazelnut.
At week 44, the children were fed all three of their food allergens in amounts equivalent to about 20 peanuts or a half-cup of milk.
The lower results for children on oral immunotherapy were driven by the fact that more of these kids had to drop out of the study due to adverse reactions, researchers said.
About 88% of children treated with omalizumab finished the stage 2 trial, compared with 51% of those receiving oral immunotherapy, results show.
No children taking omalizumab experienced serious adverse reactions, compared with more than 30% of those treated with oral immunotherapy.
"We have demonstrated that there are multiple paths to living a safe life with food allergies," senior researcher Dr. Sharon Chinthrajah, acting director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford Medicine, said in a news release.
"This study is very encouraging because it shows that we have treatment choices for our patients that are safe and not too burdensome," she added.
Researchers at the AAAAI meeting also presented preliminary results from stage 3 of the clinical trial, which focused on the first 60 children in the study.
Stage 3 focused on different pathways that children with food allergies might take in real-world settings, after they've gained tolerance to trigger foods through omalizumab therapy.
Each of the children was assigned one of three strategies for each of their food allergens -- start eating the food, continue with oral immunotherapy or avoid the food.
These strategies were assigned based on how the kids responded to a food challenge following omalizumab treatment.
More than 80% of the plans began with the kids eating the foods to which they'd been allergic, results show.
The kids were then tracked for a year to see how they fared.
Preliminary results show that consumption of milk, egg and wheat had a greater success rate (61% to 70%) than peanuts and tree nuts (38% to 56%).
In most cases, kids ate declining amounts of their allergens during the follow-up period. Some adverse events occurred, including food reactions severe enough to require an epinephrine shot.
Stage 3 is ongoing, with completion expected this summer, researchers said.
"While the results of Stage 3 are still preliminary, the majority of the first 60 participants were able to successfully introduce allergenic foods into their diet after stopping omalizumab," lead researcher Dr. Jennifer Dantzer, a pediatric allergist at Johns Hopkins Children's Center, said in a news release.
"Omalizumab is currently approved in the U.S. for the reduction of allergic reactions that may occur with accidental exposures," Dantzer said. "These results indicate that omalizumab may have additional uses that may be valuable for patients, but the potential risks should be recognized."
Funding for the clinical trial came from Genentech and Novartis, the makers of omalizumab.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The American Academy of Allergy, Asthma & Immunology has more about food allergies.
Copyright © 2025 HealthDay. All rights reserved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Improve Asthma by Targeting Common Triggers
Improve Asthma by Targeting Common Triggers

Medscape

time2 hours ago

  • Medscape

Improve Asthma by Targeting Common Triggers

This transcript has been edited for clarity. Asthma is a disease that affects 20% of the American population. This means that 20% of people wake up with shortness of breath, wheezing, or tightness in their chest, which is extremely uncomfortable. Common triggers that we can modify to help these patients include GERD (gastroesophageal reflux disease), which is the most common. Acid reflux can backflow into the lungs causing bronchoconstriction, shortness of breath, and wheezing, especially when someone is laying down. Treating GERD with diet modification and sometimes Pepcid or Protonix can be beneficial. Other triggers that we look for include postnasal drip or allergies. Allergies and postnasal drip can significantly impact asthma by once again leading to bronchoconstriction through mucus congestion, causing more buildup within the lungs and the smaller airways that can cause decreased breathing and shortness of breath. By treating them with Singulair — montelukast over the counter — Allegra, or even Flonase for nasal symptoms and sinus symptoms, this can significantly impact and decrease shortness of breath. The last trigger that we do look at is weight associated with obstructive sleep apnea. Sleep apnea can increase CO 2 within the body as ventilation decreases, and this can also lead to wheezing, shortness of breath, and increase asthma symptoms. Weight can significantly impact a patient's ability to inhale and exhale that can then, once again, induce asthmatic symptoms.

Top 3 Chronic Urticaria Treatments Highlighted in Meta-Analysis
Top 3 Chronic Urticaria Treatments Highlighted in Meta-Analysis

Medscape

timea day ago

  • Medscape

Top 3 Chronic Urticaria Treatments Highlighted in Meta-Analysis

In managing antihistamine-refractory chronic urticaria, omalizumab and remibrutinib stand out among the most effective treatments across multiple patient-important outcomes, followed by dupilumab, which shows improvement in urticaria activity, according to a meta-analysis of 42 systemic treatments in 93 studies. All three treatments for chronic urticaria, a condition defined by wheal and itch symptoms persisting 6 weeks or more, have favorable safety profiles, according to the researchers, led by Alexandro W. L. Chu, MD, with the Department of Medicine and the Evidence in Allergy Group at McMaster University in Hamilton, Ontario, Canada. Findings were published in The Journal of Allergy and Clinical Immunology as part of an update of chronic urticaria guidelines for the American Academy of Allergy, Asthma & Immunology (AAAAI), American College of Allergy, Asthma & Immunology (ACAAI), and Joint Task Force on Practice Parameters (JTFPP). The meta-analysis examined patient-important outcomes beyond itch and wheal assessment such as angioedema, sleep quality, urticaria- and angioedema-related quality of life, and adverse events at the longest available time point. The researchers used measures including the 7-day Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire and Angioedema Quality of Life Questionnaire. Dupilumab improves itch and wheals, 'but it is uncertain whether it improves angioedema or quality of life,' the researchers wrote. Cyclosporine, while it may be among the most effective, the analysis noted, may also be among the most harmful treatments with a high frequency of adverse events. In the intermediate range of effectiveness is low-dose omalizumab (doses below the standard 300 mg or administration less frequent than every 4 weeks) and that low dose also has a favorable safety profile, the data showed. 'Azathioprine, dapsone, hydroxychloroquine, mycophenolate, sulfasalazine, and vitamin D may improve outcomes, while benralizumab, quilizumab, and tezepelumab may not differ from placebo, though the evidence is uncertain,' the report stated. 'Findings were consistent across age groups and baseline severity and were robust to subgroup analyses.' Patients' comorbidities may also steer treatment selection, the authors wrote. 'For instance, patients with concomitant food allergies may favor omalizumab, while those with chronic rhinosinusitis with nasal polyposis or atopic dermatitis may favor dupilumab.' Remibrutinib Rachel Meltzer, MD, MPH, director of the Pruritus Clinic at Brigham and Women's Hospital and instructor in dermatology at Harvard Medical School, both in Boston, told Medscape Medical News the most important aspect of the meta-analysis is the side-by-side comparison of the treatments, particularly the comparison with the bruton tyrosine kinase inhibitor remibrutinib, which, she noted, is not yet approved by the FDA for any indication in dermatology. 'The only people who have any clinical experience with it are the people running the trials at the moment,' she said, and information from them indicates that 'remibrutinib does sound promising. The exciting thing is that it's an oral medicine and it seems to have a good safety and efficacy profile, whereas now, if someone fails our standard oral regimen, the move frequently has been to go to Zolair/omalizumab or less frequently in dermatology, cyclosporine.' 'Omalizumab has been approved for quite some time and that's been kind of the go-to if you need to escalate therapy if people fail the first-line high-dose antihistamines,' she said. Dupilumab, she said, 'wouldn't be the first thing I'd try unless someone had a comorbidity of atopic dermatitis or asthma or allergic rhinitis with nasal polyps,' she said. It was approved in April for chronic spontaneous urticaria. This is the first review of chronic urticaria treatments that has 'systematically analyzed the overall relative benefits and harms of all available options or appraised the evidence using robust and standardized approaches,' the authors wrote. This study was commissioned by the AAAAI and the ACAAI through the JTFPP. Several authors reported multiple ties to pharmaceutical companies, which are available with the full text. Meltzer reported no relevant financial relationships.

Citryll Announces Formation of Scientific Advisory Board
Citryll Announces Formation of Scientific Advisory Board

Yahoo

time2 days ago

  • Yahoo

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces the formation of its Scientific Advisory Board (SAB). The Board will provide strategic guidance and scientific insight as Citryll advances the development of CIT-013, its first-in-class monoclonal antibody, through the clinic. The SAB brings together internationally recognised experts in NET biology, pre-clinical development, and immunology. The founding members include Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood and Professor Paul Kubes. 'We are honoured to welcome this distinguished group of experts to Citryll's Scientific Advisory Board,' said Eric Meldrum, Chief Scientific Officer of Citryll. 'Their combined expertise will be invaluable as we advance CIT-013 in ongoing trials in rheumatoid arthritis and hidradenitis suppurativa. With their guidance, we aim to unlock the full therapeutic potential of targeting extracellular traps in a range of inflammatory diseases. This is an important step in strengthening our broader advisory network, as we also work to build a Clinical Advisory Board to support our next stage of clinical development.' Members of Citryll's Scientific Advisory Board include: Dr. Tim Hammond, PhD Tim brings over 35 years of experience in pharmaceutical drug discovery and development. He is currently Head of Safety at various companies and was formerly Vice President of Safety Assessment in the UK for AstraZeneca. He has been an independent consultant since 2012. Tim is a past President of the British Toxicology Society, is a Fellow of the Royal College of Pathologists, is a member of the American Society of Toxicology and was a founding member of the International Safety Pharmacology Society, which awarded him the Distinguished Scientist Award in 2007. He holds a PhD in Pharmacology and Toxicology from the University of Birmingham and an Honorary Professorship from the University of Liverpool. Professor John Hamilton, PhD John is internationally recognised for his expertise in macrophage biology and inflammation, with his research significantly contributing to the understanding of inflammatory mechanisms in diseases such as rheumatoid arthritis. He has received numerous honours, including the Australian Rheumatology Association Distinguished Service Medal, the American College of Rheumatology Distinguished Basic Investigator Award, and the International Association of Inflammation Societies Lifetime Achievement Award. He is a Professor in the Department of Medicine at the University of Melbourne and a Fellow of the Australian Academy of Science. He holds a PhD in Chemistry from the University of Melbourne. Dr. Christian Lood, PhD Christian is a leading researcher in neutrophil function, NET formation, and the role of innate immunity in autoimmune diseases such as systemic lupus erythematosus. His work has provided critical insights into how NETs contribute to autoimmune pathology and therapeutic intervention opportunities. He is currently an Associate Professor, Division of Rheumatology at the University of Washington with a focus in neutrophil biology in inflammatory and autoimmune conditions. He holds a PhD in Biomedicine from Lund University. Professor Paul Kubes, PhD Professor Paul Kubes is known internationally for his expertise in leukocyte recruitment and inflammation, with significant contributions to understanding immune cell function in inflammatory disease and tissue repair. He is a professor at Queen's University, where he recently accepted a Canada Excellence Research Chair. Prior to this, he was a Professor at the University of Calgary Cumming School of Medicine and the Founding Director of the Snyder Institute for Chronic Disease for 15 years. He also holds a Canada Research Chair in Leukocyte Recruitment in Inflammatory Disease. Professor Paul Kubes has received numerous awards, including the CIHR Investigator of the Year and the Henry Friesen Award, and has published in leading journals such as Cell, Science, and Nature. He holds a (Honours) in Biological Sciences, an M.S. in Physiology, and a Ph.D. in Physiology from Queen's University. -ENDS- About Citryll Citryll is pioneering a transformative approach to treating inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically. Citryll is developing the first NET-targeting therapy and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases. Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action: it enhances the clearance of existing NETs and inhibits the formation of new NETs. By addressing this key driver of inflammation, CIT-013 has the potential to offer a differentiated and comprehensive treatment option for conditions such as rheumatoid arthritis and hidradenitis suppurativa, where current therapies often fall short of providing adequate disease control. Contacts CitryllSjoerd van Gorp, COOEmail: info@ Citryll Media ContactsICR HealthcareAmber Fennell, Stephanie Cuthbert, Lucy FeatherstoneEmail: citryll@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store